Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

Benefits of stemming bovine TB need to be demonstrated

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Author information

Authors and Affiliations

Authors

Additional information

Contributions may be submitted to correspondence@nature.com.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Torgerson, P., Torgerson, D. Benefits of stemming bovine TB need to be demonstrated. Nature 457, 657 (2009). https://doi.org/10.1038/457657d

Download citation

  • Published:

  • Issue date:

  • DOI: https://doi.org/10.1038/457657d

Comments

Commenting on this article is now closed.

  1. Some of the comments in this publication are factually incorrect. Zoonotic disease resulting in large economic impacts are not 'one-offs', and this is applicable to a UK context alone, not just overseas. Surely the author's memory isn't so bad that he's forgotten mad cow disease. The ramifications are still being felt globally today, and it resulted not just in economic losses, but in loss of human lives, too. In Europe, over 500 million Euro are estimated to be lost within the dairy sector due to M. bovis. In New Zealand, the recent spread of M. bovis (i.e. mycoplasma not mycobacterium), is currently causing severe economic devastation. Are there any declared conflicts of interest associated with this paper? I can't find the section if there is one, and would like to take a look at it, please let me know.

  2. If current programmes attempting to reduce bovine TB aren't working in the UK, perhaps it ought to look at its methodologies, and whether industry is being compliant. Here, in New Zealand, our anti-TB programme is regarded as having been greatly successful. It is even the aim of health authorities to entirely eliminate the disease within the next decade. You've got to ask yourself, if we can do it, what are you doing wrong? My view is that trying to fight to maintain current industry practice, rather than support effort to deal to the problem, may likely be a significant issue.

Search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing